The Azivudine Tablet Developed by Professor Chang Junbiao of Zhengzhou University for the Treatment of COVID-19 has Reached the Expectation of the Main Efficacy Indicators in the Phase III Clinical Trial of COVID-19 Indication Registration.-Zhengzhou University

Azivudine, which has been approved for phase IlI clinical trials for more than two years, is expected to become China's first oral anti-COVID-19 drug with fully independent intellectual property. On July 15, Henan Genuine Biotech

Co., LTD. announced that it had recently formally submitted the marketing

application for Azvudine for the treatment of COVID-19 to the National Medical Products Administration.